Feldan Therapeutics Announces Publication in Nature Communications

Utilizing Shuttle technology, the Feldan team and their collaborators, including TransBIOTech's teams, have successfully demonstrated for the first time the feasibility of base editing in the lungs of non-human primates. This study provides in vivo proof-of-concept for functional delivery to lung cells in this model, highlighting the therapeutic potential of the Feldan Shuttle as a delivery agent for lung cells and in the development of treatments for pulmonary diseases. Feldan extends its gratitude to its collaborators from the University of Iowa, University of Davis, Johns Hopkins University School of Medicine, Harvard University, Integrated DNA Technologies, and TransBIOTech for this achievement.

Read the article here: https://www.nature.com/articles/s41467-023-43904-w

‍